CA3101556A1 - Ccr5 inhibitor for use in treating cancer - Google Patents

Ccr5 inhibitor for use in treating cancer Download PDF

Info

Publication number
CA3101556A1
CA3101556A1 CA3101556A CA3101556A CA3101556A1 CA 3101556 A1 CA3101556 A1 CA 3101556A1 CA 3101556 A CA3101556 A CA 3101556A CA 3101556 A CA3101556 A CA 3101556A CA 3101556 A1 CA3101556 A1 CA 3101556A1
Authority
CA
Canada
Prior art keywords
seq
cancer
ccr5
signature sequence
ccr5 inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3101556A
Other languages
English (en)
French (fr)
Inventor
Oliver Hartley
Robin Ewart Offord
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Biotechnology Switzerland SARL
Original Assignee
Orion Biotechnology Switzerland SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Biotechnology Switzerland SARL filed Critical Orion Biotechnology Switzerland SARL
Publication of CA3101556A1 publication Critical patent/CA3101556A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA3101556A 2018-05-28 2019-05-24 Ccr5 inhibitor for use in treating cancer Pending CA3101556A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862677114P 2018-05-28 2018-05-28
US62/677,114 2018-05-28
US201962792600P 2019-01-15 2019-01-15
US62/792,600 2019-01-15
PCT/IB2019/054350 WO2019229616A1 (en) 2018-05-28 2019-05-24 Ccr5 inhibitor for use in treating cancer

Publications (1)

Publication Number Publication Date
CA3101556A1 true CA3101556A1 (en) 2019-12-05

Family

ID=67480241

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3101556A Pending CA3101556A1 (en) 2018-05-28 2019-05-24 Ccr5 inhibitor for use in treating cancer

Country Status (11)

Country Link
US (1) US20210205411A1 (https=)
EP (1) EP3813870B1 (https=)
JP (2) JP7319020B2 (https=)
KR (1) KR20210016398A (https=)
CN (1) CN112469429B (https=)
AU (1) AU2019276939A1 (https=)
BR (1) BR112020024328A2 (https=)
CA (1) CA3101556A1 (https=)
MX (1) MX2020012782A (https=)
WO (1) WO2019229616A1 (https=)
ZA (1) ZA202007955B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021019405A2 (pt) * 2019-04-01 2021-11-30 Cytodyn Inc Agentes anti-ccr5 e métodos de tratamento que bloqueiam a metástase do câncer ou aumentam a morte celular induzida pela quimioterapia prejudicial ao dna
WO2021231648A2 (en) * 2020-05-12 2021-11-18 Gigagen, Inc. Cancer therapeutics comprising chemokine or its analog
WO2024146707A1 (en) * 2023-01-06 2024-07-11 Université De Genève Variant ligand conjugates for payload delivery
WO2025172252A1 (en) 2024-02-15 2025-08-21 Novo Nordisk A/S Protracted ccr5 antagonists and uses thereof
WO2025176787A1 (en) * 2024-02-22 2025-08-28 Orion Biotechnology Holding Sa Ccl5 variants for modulating gpr75

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0614755D0 (en) * 2006-07-25 2006-09-06 Univ Geneve Cytokine derivatives
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
US8916696B2 (en) * 2011-06-12 2014-12-23 City Of Hope Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use
ES2800316T3 (es) * 2011-06-13 2020-12-29 Tla Targeted Immunotherapies Ab Tratamiento del cáncer
JP6518585B2 (ja) * 2012-05-14 2019-05-22 リチャード ジー． ペステル がんの治療のためのｃｃｒ５の修飾薬の使用
US20150250837A1 (en) * 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
EP3212228B1 (en) * 2014-10-27 2025-12-03 Ruprecht-Karls-Universität Heidelberg Maraviroc alone or in combination therapy for the treatment of cancer
AR105654A1 (es) * 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)

Also Published As

Publication number Publication date
CN112469429A (zh) 2021-03-09
JP2021525770A (ja) 2021-09-27
EP3813870A1 (en) 2021-05-05
EP3813870C0 (en) 2023-11-15
BR112020024328A2 (pt) 2021-02-23
WO2019229616A1 (en) 2019-12-05
MX2020012782A (es) 2021-04-28
KR20210016398A (ko) 2021-02-15
EP3813870B1 (en) 2023-11-15
ZA202007955B (en) 2022-06-29
CN112469429B (zh) 2025-02-14
JP7319020B2 (ja) 2023-08-01
JP2023134704A (ja) 2023-09-27
US20210205411A1 (en) 2021-07-08
AU2019276939A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
EP3813870B1 (en) Ccr5 inhibitor for use in treating cancer
US11365184B2 (en) Antiproliferative compounds, and their pharmaceutical compositions and uses
US10973822B2 (en) Combination therapy for treatment of hematological cancers and solid tumors
WO2012050374A2 (en) Immunotherapy for solid tumors
US7893045B2 (en) Methods for treating lymphomas in certain patient populations and screening patients for said therapy
US12090147B2 (en) Combination therapy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
EP3906030A1 (en) Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5yl) methyl)-2,2-difluoroacetamide
CA2766322A1 (en) Methods of using corticotropin-releasing factor for the treatment of cancer
HK40048943A (en) Ccr5 inhibitor for use in treating cancer
HK40051637B (en) Antiproliferative compounds for use in the treatment of leukemia
HK40051637A (en) Antiproliferative compounds for use in the treatment of leukemia
WO2018156680A1 (en) Treatment of refractory of relapsed hematological cancer with durvalumab
HK1262667A1 (en) Antiproliferative compounds, and their pharmaceutical compositions and uses
HK1262667B (en) Antiproliferative compounds, and their pharmaceutical compositions and uses

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240521

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250521

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250521